Ignite Creation Date:
2024-07-17 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06492616
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-07-01
Brief Title:
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ERHER2- Early Breast Cancer With High Risk of Recurrence
Sponsor:
Stemline Therapeutics Inc
Organization:
Stemline Therapeutics Inc
Organization Data
Organization:
Stemline Therapeutics Inc
Class:
OTHER
Study ID:
STML-ELA-0422
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Stemline Therapeutics Inc
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None